CQDM THTX and CQDM are working on research projects related to metastasis cancers.
https://www.theratech.com/news-releases/news-release-details/cqdm-quebec-breast-cancer-foundation-and-theratechnologies-fund/
"The SAB is a key committee of CQDM as it provides strategic orientations in biopharmaceutical innovation and oversees the selection and monitoring of projects funded by CQDM.
Kuldeep Neote is an Entrepreneur-in-Residence at the National Institutes of Health and at FACIT/OICR, an investment firm focused on accelerating the commercialization of oncology innovations and located in Toronto. Kuldeep is a molecular biologist by training and has many years of experience in drug discovery in the areas of immunology, inflammation and oncology. Among other things, he has established a drug discovery platform for chemokine receptors, which has led to the discovery and development of several clinical candidates. In recent years, Kuldeep has worked as an advisor to identify scientifically innovative and commercially viable candidates for partnership or investment. His rich and impressive track record in various pharmaceutical companies and his long-standing interest in integrating cutting-edge scientific discoveries into drug discovery programs, gives him a unique expertise that will be a major asset to the SAB and CQDM."
CQDM nominates Kuldeep Neote